Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teriparatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R known ✓ | Q03431 | 14/20 | 0.85 |
| ▸ | GLP1R | P43220 | 6/20 | 0.71 |
| ▸ | CCKBR | P32239 | 1/20 | 0.71 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28980125 | 0.97 | PTH1R (0.80) | PTH1RGLP1RCCKBR | |
| Teriparatide SCHEMBL29394193 | 0.97 | PTH1R (0.80) | PTH1RGLP1RCCKBR | |
| Teriparatide SCHEMBL30645329 | 0.97 | PTH1R (0.80) | PTH1RGLP1RCCKBR | |
| SCHEMBL30255063 | 0.97 | PTH1R (0.80) | PTH1RGLP1RCCKBR | |
| Teriparatide SCHEMBL30448707 | 0.97 | PTH1R (0.80) | PTH1RGLP1RCCKBR | |
| SCHEMBL28980015 | 0.97 | PTH1R (0.91) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teriparatide SCHEMBL29354459 | 0.97 | PTH1R (0.91) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teriparatide SCHEMBL720581 | 0.96 | PTH1R (0.90) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL30975122 | 0.95 | PTH1R (0.78) | PTH1RGLP1RCCKBR | |
| SCHEMBL30449343 | 0.95 | PTH1R (0.77) | PTH1RGLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4054407-B1 | STIMULATION DEVICES AND SYSTEMS | UNITED THERAPEUTICS CORP (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611412-B2 | Targeting the TLK1/NEK1 axis in prostate cancer | BOARD OF SUPERVISORS OF LOUISANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-04-28 | — | — | US | claimed |
| EP-4442277-B1 | STABILIZED ANTIBODY-CONTAINING LIQUID FORMULATIONS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-04-22 | — | — | EP | claimed |
| EP-4081210-B1 | PHARMACEUTICAL COMPOSITION OF CASR MODULATORS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2026-04-15 | — | — | EP | claimed |
| US-20260076999-A1 | PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACE | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260007571-A1 | PHARMACEUTICAL CONTAINER WITH PH PROTECTIVE LAYER DEPOSITED BY ATOMIC LAYER DEPOSITION | INNOVATIVE SCIENTIFIC PRODUCTS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2025245470-A1 | SYRINGE WITH BUILT-IN LUBRICATION FOR MEDICAL USE | INNOVATIVE SCIENTIFIC PRODUCTS, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20220370528-A1 | USE OF PROBIOTIC YEAST CELLS PRODUCING RECOMBINANT PARATHORMONE FOR THERAPEUTIC PURPOSES | NANOMIK BIYOTEKNOLOJI ANANIM SIRKETI (TR) | 2022-11-24 | — | — | US | claimed |
| US-20220370802-A1 | STIMULATION DEVICES, SYSTEMS, AND METHODS | UNITED THERAPEUTICS CORPORATION (US) | 2022-11-24 | — | — | US | claimed |
| EP-3659624-B1 | CARTILAGE TARGETING AGENTS AND THEIR USE | US HEALTH (US) | 2022-11-16 | — | — | EP | claimed |
| US-20220289812-A1 | ELP FUSION PROTEINS COMPRISING PARATHYROID HORMONE FOR CONTROLLED AND SUSTAINED RELEASE | Immunoforge Co., Ltd. (KR) | 2022-09-15 | — | — | US | claimed |
| EP-4054407-A1 | STIMULATION DEVICES, SYSTEMS, AND METHODS | United Therapeutics Corp. (US) | 2022-09-14 | — | — | EP | claimed |
| EP-3244878-B1 | SOLID ORAL DOSAGE FORMS | ENTERIS BIOPHARMA INC (US) | 2022-08-10 | — | — | EP | claimed |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2022-03-22 | — | — | US | claimed |
| EP-2814504-B1 | PROTEASE INHIBITOR-CONTAINING COMPOSITIONS, COMPOSITIONS COMPRISING SAME, AND METHODS FOR PRODUCING AND USING SAME | ORAMED LTD (IL) | 2022-03-16 | — | — | EP | claimed |
| EP-3359129-B1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | KINDEVA DRUG DELIVERY LP (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3942016-A1 | NOVEL LACTIC ACID BACTERIA STRAINS THAT PROMOTE THE ABSORPTION OF CALCIUM - PEPTIDES AND ASSOCIATED PRODUCTS | VF Bioscience (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | PTH1R 1/4885GLP1R 83/4885CCKBR 138/4885 |
| US-20260007571-A1 | PHARMACEUTICAL CONTAINER WITH PH PROTECTIVE LAYER DEPOSITED BY ATOMIC LAYER DEPOSITION | CFD, SLC9B2, SETD1B | PTH1R 1950/4885GLP1R 1317/4885CCKBR 2789/4885 |
| US-11279922-B2 | Delivery of therapeutic agents by a collagen binding protein | PTH1R, GHRHR, FGF23 | PTH1R 1/4885GLP1R 134/4885CCKBR 148/4885 |
| US-20260076999-A1 | PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACE | IAPP, PTH1R, VEGFA | PTH1R 2/4885GLP1R 23/4885CCKBR 99/4885 |
| US-12611412-B2 | Targeting the TLK1/NEK1 axis in prostate cancer | NEK5, NEK3, PLK3 | PTH1R 591/4885GLP1R 629/4885CCKBR 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.